Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EA-230 in Experimental Human Endotoxemia
NCT02629874Phase 1Completed
- Sponsor
- Radboud University Medical Center
- Start
- Feb 2015
- Primary completion
- Jul 2015
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of EA-230 in Systemic Inflammatory Response Syndrome (SIRS) (4 arms), sponsored by Radboud University Medical Center. Primary endpoint: Safety and tolerability expressed in treatment related (serious) adverse events at day 14. Started Feb 2015; status: completed.
02
Drugs
EA-230
03
Conditions
Systemic Inflammatory Response Syndrome (SIRS)
Beyond the preview
Go deeper on NCT02629874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02629874.